PURPOSE OF THE RESEARCH: To attempt to replicate the associations found in our previous study of patients and family caregivers between interleukin 6 (IL6) and nuclear factor kappa beta 2 (NFKB2) and sleep disturbance and to identify additional genetic associations in a larger sample of patients with breast cancer. METHODS AND SAMPLE: Patients with breast cancer (n = 398) were recruited prior to surgery and followed for six months. Patients completed a self-report measure of sleep disturbance and provided a blood sample for genomic analyses. Growth mixture modeling was used to identify distinct latent classes of patients with higher and lower levels of sleep disturbance. KEY RESULTS: Patients who were younger and who had higher comorbidity and lower functional status were more likely to be in the high sustained sleep disturbance class. Variations in three cytokine genes (i.e., IL1 receptor 2 (IL1R2), IL13, NFKB2) predicted latent class membership. CONCLUSIONS: Polymorphisms in cytokine genes may partially explain inter-individual variability in sleep disturbance. Determination of high risk phenotypes and associated molecular markers may allow for earlier identification of patients at higher risk for developing sleep disturbance and lead to the development of more targeted clinical interventions.
PURPOSE OF THE RESEARCH: To attempt to replicate the associations found in our previous study of patients and family caregivers between interleukin 6 (IL6) and nuclear factor kappa beta 2 (NFKB2) and sleep disturbance and to identify additional genetic associations in a larger sample of patients with breast cancer. METHODS AND SAMPLE: Patients with breast cancer (n = 398) were recruited prior to surgery and followed for six months. Patients completed a self-report measure of sleep disturbance and provided a blood sample for genomic analyses. Growth mixture modeling was used to identify distinct latent classes of patients with higher and lower levels of sleep disturbance. KEY RESULTS:Patients who were younger and who had higher comorbidity and lower functional status were more likely to be in the high sustained sleep disturbance class. Variations in three cytokine genes (i.e., IL1 receptor 2 (IL1R2), IL13, NFKB2) predicted latent class membership. CONCLUSIONS: Polymorphisms in cytokine genes may partially explain inter-individual variability in sleep disturbance. Determination of high risk phenotypes and associated molecular markers may allow for earlier identification of patients at higher risk for developing sleep disturbance and lead to the development of more targeted clinical interventions.
Authors: Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler Journal: Science Date: 2002-05-23 Impact factor: 47.728
Authors: Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue Journal: Am J Hum Genet Date: 2003-06 Impact factor: 11.025
Authors: Zhou Zhu; Tao Zheng; Robert J Homer; Yoon-Keun Kim; Ning Yuan Chen; Lauren Cohn; Qutayba Hamid; Jack A Elias Journal: Science Date: 2004-06-11 Impact factor: 47.728
Authors: F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani Journal: Science Date: 1993-07-23 Impact factor: 47.728
Authors: Christina Van Onselen; Bradley E Aouizerat; Laura B Dunn; Steven M Paul; Claudia West; Deborah Hamolsky; Kathryn Lee; Michelle Melisko; John Neuhaus; Christine Miaskowski Journal: Breast Date: 2012-08-01 Impact factor: 4.380
Authors: Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski Journal: Qual Life Res Date: 2016-05-09 Impact factor: 4.147
Authors: Bradley E Aouizerat; Anand Dhruva; Steven M Paul; Bruce A Cooper; Kord M Kober; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-05-29 Impact factor: 3.612
Authors: Kimberly Alexander; Yvette P Conley; Jon D Levine; Bruce A Cooper; Steven M Paul; Judy Mastick; Claudia West; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-09-23 Impact factor: 3.612
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Bruce A Cooper; Judy Mastick; Melissa Mazor; Melisa Wong; Steven M Paul; Yvette P Conley; Thierry Jahan; Christine Ritchie; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2018-08-22 Impact factor: 2.398
Authors: Marshall Gold; Laura B Dunn; Bethany Phoenix; Steven M Paul; Deborah Hamolsky; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2015-07-15 Impact factor: 2.398
Authors: Christine Miaskowski; Yvette P Conley; Judy Mastick; Steven M Paul; Bruce A Cooper; Jon D Levine; Mitchell Knisely; Kord M Kober Journal: J Pain Symptom Manage Date: 2017-08-08 Impact factor: 3.612
Authors: Kord M Kober; Betty Smoot; Steven M Paul; Bruce A Cooper; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2016-09-21 Impact factor: 3.612
Authors: Christine Miaskowski; Janine K Cataldo; Christina R Baggott; Claudia West; Laura B Dunn; Anand Dhruva; John D Merriman; Dale J Langford; Kord M Kober; Steven M Paul; Bruce A Cooper; Bradley E Aouizerat Journal: Support Care Cancer Date: 2014-09-24 Impact factor: 3.603
Authors: Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon Journal: Support Care Cancer Date: 2018-10-20 Impact factor: 3.603
Authors: Terri S Armstrong; Marcia Y Shade; Ghislain Breton; Mark R Gilbert; Anita Mahajan; Michael E Scheurer; Elizabeth Vera; Ann M Berger Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300